Study to Evaluate Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors

Study Title
A Study to Evaluate 5 ־¼g/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement
Teva Identifier
XM02-ONC-201 | 2014-001772-55
ClinicalTrials.gov Identifier
NCT02190721
Study Status
Completed
Trial Condition(s)
Neutropenia
Interventions
Drug: tbo-filgrastim

Study Description

Please refer to ClinicalTrials.gov for a description of the trial



Key Participation Requirements

Gender
Female, Male
Age Range
1 Month to 16 Years
Trial Duration
May 12, 2015 - April 4, 2017
Phase
Phase 2

Study Type

Interventional